RecruitingNCT06969170
Psilocybin for adults with generalized anxiety: safety and early effects
About this title
Read the official source — NCT06969170Researchers are comparing Psilocybin (drug) and placebo, tracking side effects to assess safety and tolerability in adults with an anxiety condition.
Medication studyAges 18–60Canada
Understand this study
What is this study about?
Researchers are comparing Psilocybin (drug) and placebo, tracking side effects to assess safety and tolerability in adults with an anxiety condition.
Who could participate?
This study is for people with anxiety. Listed age limits: 18 years to 60 years. Other eligibility criteria apply.
- Listed locations
- KingstonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 16, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 50
- Sponsor
- Claudio N Soares
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT06969170
- Official title
Show the full official title
A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Kingston
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing Psilocybin (drug) and placebo, tracking side effects to assess safety and tolerability in adults with an anxiety condition.
Who is behind this study?
The study sponsor is Claudio N Soares.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin (drug).
Who can participate?
This study is for people with anxiety. Listed age limits: 18 years to 60 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
